Pharma Focus Asia
Klöckner Pentaplast - Pentapharm® alfoil® films

Driving value creation through medical affairs in China

Summary:

After more than three decades of fast economic growth, China has entered the “new normal” stage, marked by a moderate and stable domestic GDP growth rate. Healthcare has been elevated to a national level agenda by the current leadership with the releasing of “China Health 2030”.

In addition, “Made in China 2025” (shown in Figure 1) has also demonstrated Chinese government’s mission to foster innovation while continuing to enhance drug safety and improve healthcare service quality.

Download '.pdf' Format of the whitepaper.

Download Whitepapers
magazine-slider-imageBIOVIA from Molecule to MedicineMFA + MMA 2024CPHI China || PMEC China 2024Asia Healthcare Week 2024Advance DoE WorkshopCPHI Korea 2024CHEMICAL INDONESIA 2024INALAB 2024 Thermo Scientific - DynaDrive and DynaSpinRehab Expo 2024ISPE Singapore Affiliate Conference & Exhibition 20242024 PDA Cell and Gene Pharmaceutical Products Conference 2024 PDA Aseptic Manufacturing Excellence Conference2024 PDA Aseptic Processing of Biopharmaceuticals Conference3rd World ADC Asia 2024LogiPharma Asia 2024